Koyfin Home > Directory > Health Care > Gilead Sciences Inc > Capital Expenditures

Gilead Sciences Inc Capital Expenditures Chart (GILD)

Gilead Sciences Inc annual/quarterly Capital Expenditures from 2010 to 2020.
  • Gilead Sciences Inc Capital Expenditures for the quarter ending September 09, 2020 was $-155m a -30.97% increase of 48m year over year
  • Gilead Sciences Inc Capital Expenditures for the last 12 months ending September 09, 2020 was $-672m a -22.77% increase of 153m year over year
  • Gilead Sciences Inc Annual Capital Expenditures for 2019 was $-825m a -12.00% increase of 99m from 2018
  • Gilead Sciences Inc Annual Capital Expenditures for 2018 was $-924m a 36.15% decrease of -334m from 2017
  • Gilead Sciences Inc Annual Capital Expenditures for 2017 was $-590m a -26.78% increase of 158m from 2016
Other Cash Flow Metrics:
  • Gilead Sciences Inc Cash Flow from Operations for the quarter ending September 09, 2018 was $2,212m a -24.46% decrease of -541m year over year
  • Gilead Sciences Inc Levered Free Cash Flow (FCF) for the quarter ending September 09, 2018 was $1,592m a -123.19% decrease of -1,962m year over year
  • Gilead Sciences Inc Total Revenue for the quarter ending December 12, 2018 was $5,795m a 12.20% increase of 707m year over year
View Chart On Koyfin

Quarterly GILD Capital Expenditures Data

09/2020$-155m
06/2020$-143m
03/2020$-171m
12/2019$-203m
09/2019$-200m
06/2019$-185m
03/2019$-237m
12/2018$-248m
09/2018$-167m
06/2018$-297m

Annual GILD Capital Expenditures Data

2019$-825m
2018$-924m
2017$-590m
2016$-748m
2015$-747m
2014$-557m
2013$-190m
2012$-397m
2011$-132m
2010$-62m